
prof. MUDr. Spyridon Gkalpakiotis, Ph.D.



<div class="skolitel"></div>

Department of Dermatovenereology, Third Faculty of Medicine,
Charles University and University hospital of Kralovske Vinohrady, Prague
<https://www.lf3.cuni.cz/3LF-998.html>

Topic title

Immunothrombosis - a new therapeutic target for the prevention of major cardiovascular events in patients with psoriasis?

Description of scientific activity

Spyridon Gkalpakiotis graduated from the 3rd Faculty of Medicine, Charles University in Prague in 2005. After graduating, he joined the Department of Dermatovenereology, 3rd Faculty of Medicine, Charles University and University hospital of Kralovske Vinohrady, where he is working till now. In 2010, he defended his PhD degree on "Evaluation of the success of adjuvant melanoma therapy using real time RT-PCR". From 2013 he is the vice-chairman of the department and from December 2018 he has the degree of associate professor at the 3rd Faculty of Medicine, Charles University where he teaches students of general medicine and he is a supervisor for postgraduate students in the biomedicine program. He has 48 publications in pubmed and his H-index is 9. In 2010, he received a gold award at the 22nd World Congress of Dermatology in Seoul, Korea, for the best poster describing the results of his dissertation on the topic of circulating melanoma cells. At present, he specializes mainly in psoriasis, atopic dermatitis and on biologic therapy. New insights in the pathophysiology of different inflammatory skin diseases like psoriasis and atopic dermatitis have introduced modern treatment modalities such as biologic therapy. Except from the progression in treatment of these diseases we today know, that the inflammation is not only on the skin but there is a systemic inflammation which has negative results in other organs like cardiovascular system. We have shown that patients with psoriasis have increased levels of markers of systemic inflammation like IL-22, E-selectin and high sensitive CRP. Biologic therapy not only improves psoriasis on the skin but also decreases these markers which shows that has biologic therapy is suppressing the systemic inflammation. We have done research with anti TNF- α therapy, so one of the questions for further investigation is if other biologics like anti IL-17 or anti IL-23 drugs could have similar results. One other project will be focusing on the prevention of cardiovascular events in patients with psoriasis being treated with systemic therapy.

Selected publications

Gkalpakiotis Spyridon; Arenbergerová Monika; Gkalpakioti Petra; Potočková Jana; Arenberger Petr; Kraml Pavel. Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study. The Journal of Dermatology. 2017, 44(4), 363-369. IF: 2.094/2016. <Poslední známý IF: 4.005/2020>

Gkalpakiotis Spyridon; Arenbergerová Monika; Gkalpakioti Petra; Potočková Jana; Arenberger Petr; Kraml Pavel. Long Term Impact of Adalimumab Therapy on Biomarkers of Systemic Inflammation in Psoriasis: Results of a 2 year study. Dermatologic Therapy, 2020, 33(6): e14110. IF: 2.851/2020. <Poslední známý IF: 2.851/2020>

Torres Tiago; Puig Luis; Vender Ron; Lynde Charles; Piaserico Stefano; Carrascosa Jose M.; Gisondi Paolo; Daudén Esteban; Conrad Curdin; Mendes-Bastos Pedro; Ferreira Paulo; Leite Luiz; Lu Justin D.; Valerio J.; Bruni M.; Messina F.; Nidegger A.; Llamas-Velasco M.; Del Alcazar E.; Mufti A.; White Kyra; Caldarola G.; Teixeira Laetitia; Romanelli Paolo; Desai K.; Gkalpakiotis Spyridon; Romanelli Marco; Yeung Jensen; Nogueira Miguel; Chiricozzi Andrea. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study, American Journal of Clinical Dermatology, 2021, 22(4): 567-579. IF: 7.403/2020. < Poslední známý IF: 7.403/2020>

Selected or ongoing grants/clinical studies

A PHASE 3B, MULTI CENTER, OPEN-LABEL LONGTERM EXTENSION STUDY OF APREMILAST (CC10004) IN PEDIATRIC SUBJECTS FROM 6 THROUGH 17 YEARS OF AGE WITH MODERATE TO SEVERE PLAQUE PSORIASIS

A randomized, subject and investigator blinded, placebo-controlled multicenter study to assess the efficacy and safety of CMK389 in patients with moderate to severe atopic dermatitis

PhD Students

Number of current PhD students: 7

Number of defended students with year of defense: 1 PhD (2019)